ArticleFrontiers in oncology2026
Gantry-period-guided modulation factor selection in helical tomotherapy: effects on delivery efficiency, dosimetry and verification accuracy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore a gantry-period-guided strategy for identifying a lower useful modulation factor (MF) in helical tomotherapy under fixed field width and pitch. Methods: Twenty previously treated cases from head, head-and-neck, abdomen and pelvis were replanned with a field width of 2.5 cm and a pitch of 0.287. MF was initialized at 5.0 and reduced by 0.2 with unchanged objectives. At each level, plans were reoptimized and clinically reviewed. MF Results: All cases entered the efficiency-limited pathway. MF Conclusions: The MF immediately before gantry-period plateau entry may provide a practical reference point for limiting MF reduction. In this pilot cohort, this gantry-period-guided approach helped maintain plan quality and avoid reductions in modulation that offered little efficiency benefit. Further studies across additional planning configurations and disease sites will be needed to confirm its broader applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.